





HET VERANDERENDE LANDSCHAP IN DE BEHANDELING VAN MULTIPLE MYELOOM



**2021/2022
COMBINATION +mAbs
NOVEL IMMUNETHERAPY**



NOG STEEDS EEN STAMCELTRANSPLANTATIE - MAAR VOOR EN NA MEER EN LANGER

4 > 3



WELKE VRAGEN ZIJN NOG OVER?

WELKE 4?





WELKE, 1 OF 2?



4! DARATUMUMAB-VRD BETER DAN DARA-VTD?

V = BORTEZOMIB/VELCADE R=LENALIDOMIDE/REVLIMID EN D = DEXAMETHASON

FOLLOW UP ASH 2021 3-year PFS 88.9 vs 81.2%



DVTd, daratumumab, bortezomib, thalidomide, dexamethasone; D-RVd, daratumumab, bortezomib, lenalidomide, dexamethasone; PFS, progression-free survival

Moreau P et al. Lancet Oncology 2019;394(10192):29-38

Kaufman J et al. ASH 2020; abstract 549

Voorhees P et al. ASH 2021; abstract

Philippe Moreau et al., Lancet Oncol 2021, [https://doi.org/10.1016/S1470-2045\(21\)00428-9](https://doi.org/10.1016/S1470-2045(21)00428-9)



STAATSCOURANT

Officiële uitgave van het Koninkrijk der Nederlanden sinds 1814.



Nr. 29010

2 november

2022




ALS EEN STAMCELTRANSPLANTATIE GEEN OPTIE IS






MAIA STUDIE DARA-RD VS RD



No. at risk


Rd	369	333	307	280	255	237	220	205	196	179	172	155	146	133	123	113	105	94	63	36	12	4	2	0
D-Rd	368	347	335	320	309	300	290	276	266	256	246	237	232	222	210	199	195	170	123	87	51	17	5	0



No. at risk

Rd	369	351	343	336	324	317	308	300	294	281	270	258	251	241	232	223	213	183	134	85	42	14	5	1	0
D-Rd	368	350	346	344	338	334	328	316	305	302	297	286	280	273	266	255	249	228	170	118	63	22	6	1	0

CI, confidence interval; DRd, daratumumab, lenalidomide and dexamethasone; HR, hazard ratio; IV, intravenous; PFS, progression-free survival; PO, per orally; Rd, lenalidomide and dexamethasone




MAAR GELDT
DAT VOOR
IEDERE OUDERE
PATIENT?

WIL DE PATIENT DAT?
KAN HET?
NET ZO GOED?



MATE VAN FIT ZIJN BEINVLOEDT HET EFFECT VAN DE BEHANDELING



Patients at risk

Rd (fit)	78	73	69	63	61	58	53	48	47	45	41	31	20	9	3	1	1
D-Rd (fit)	68	68	67	65	63	62	61	60	58	56	53	39	28	12	2	2	0
Rd (intermediate)	122	115	104	96	81	76	71	69	68	59	55	33	20	12	7	1	0
D-Rd (intermediate)	128	127	123	118	113	109	107	101	99	95	83	67	50	31	10	3	0
Rd (frail)	169	145	134	121	112	102	95	87	79	73	65	49	24	12	0	0	0
D-Rd (frail)	172	152	145	137	133	129	122	115	109	105	97	68	53	27	12	2	1

ALS DE ZIEKTE TERUG KOMT



‘Oude middelen’

- Cyclofosfamide

Proteasoom remmers

- Ixazomib
- Carfilzomib

IMiDs

- Pomalidomide
- Iberdomide

Antistoffen

- Elotuzumab

Nieuwere middelen


- Melflufen
- Belantamab
- Selinexor






HOE WERKT THERAPIE MET ANTISTOFFEN?

Fc-dependent immune effector mechanisms and direct effects





HOE WERKT THERAPIE MET ANTISTOFFEN






NOVEL IMMUNE THERAPY APPROACHES - CAR T-CELLS AND BISPECIFIC ANTIBODIES

CAR TARGETS **BCMA** CAR-T - CILTA-CEL¹, CT103A², ARI0002H³; **GPRC5D** - MCARH1094⁴

BISABS **BCMA** - TECLISTAMAB⁵, ABBV-383⁶, REGN5458⁷; **GPRC5D** - TALQUETAMAB⁸; **FcRH5** - CEVOSTAMAB⁹





NOVEL IMMUNE THERAPY APPROACHES - CAR T-CELLS AND BISPECIFIC ANTIBODIES

CAR TARGETS **BCMA** CAR-T - CILTA-CEL¹, CT103A², ARI0002H³; **GPRC5D** - MCARH1094⁴

BISABS **BCMA** - TECLISTAMAB⁵, ABBV-383⁶, REGN5458⁷; **GPRC5D** - TALQUETAMAB⁸; **FcRH5** - CEVOSTAMAB⁹

40-65% van de patiënten was al niet meer gevoelig voor 5 middelen

Respons bijna 100%

De ziekte wordt ongeveer 9 tot 20 maanden onderdrukt


20-40% van de patiënten was al niet meer gevoelig voor 5 middelen

Respons ongeveer 70%

De ziekte wordt ongeveer 10 maanden onderdrukt



CYTOKINE RELEASE SYNDROME





VERBINDING VAN LAB EN KLINIEK




PROF. DR. NIELS VAN DE DONK

DR. MARIA THEMELI

PROF. DR. TUNA MUTIS





DR. RICHARD GROEN





TECLISTAMAB EFFECTIEVER IN PATIENTEN DIE NIET MEER REAGEREN OP DARATUMUMAB

Sequential BM samples
 $n = 8$





VERBINDEN VAN ECONOMEN EN HEMATOLOGEN




DR. HEDWIG BLOMMESTEIN



DR. DAVID CUCCHI



DR. KAZEM NASSERINEJAD




MAARTEN SEEFAT





FABULOUS STUDIE - EVEN EEN BEHANDELVRIJ INTERVAL MOGELIJK?





DE JONGEREN DIE VOOR DE OUDEREN ZORGEN - THE FRAILTIES



Claudia Stege

Febe Smits

Kaz Groen

Maarten Seefat

Kazem Nasserinejad

